

Rei Wake

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2035430/publications.pdf>

Version: 2024-02-01

28
papers

443
citations

687363

13
h-index

713466

21
g-index

28
all docs

28
docs citations

28
times ranked

669
citing authors

#	ARTICLE	IF	CITATIONS
1	The Possible Causal Link of Periodontitis to Neuropsychiatric Disorders: More Than Psychosocial Mechanisms. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3723.	4.1	55
2	Implications of Systemic Inflammation and Periodontitis for Major Depression. <i>Frontiers in Neuroscience</i> , 2018, 12, 483.	2.8	52
3	Yokukansan promotes hippocampal neurogenesis associated with the suppression of activated microglia in Gunn rat. <i>Journal of Neuroinflammation</i> , 2013, 10, 145.	7.2	36
4	Electroconvulsive shock attenuated microgliosis and astrogliosis in the hippocampus and ameliorated schizophrenia-like behavior of Gunn rat. <i>Journal of Neuroinflammation</i> , 2016, 13, 230.	7.2	32
5	Minocycline improves recognition memory and attenuates microglial activation in Gunn rat: A possible hyperbilirubinemia-induced animal model of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 50, 184-190.	4.8	31
6	Hyperbilirubinemia-related behavioral and neuropathological changes in rats: A possible schizophrenia animal model. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 581-588.	4.8	30
7	Remission of Psychosis in Treatment-Resistant Schizophrenia following Bone Marrow Transplantation: A Case Report. <i>Frontiers in Psychiatry</i> , 2017, 8, 174.	2.6	28
8	Gunn rats with glial activation in the hippocampus show prolonged immobility time in the forced swimming test and tail suspension test. <i>Brain and Behavior</i> , 2018, 8, e01028.	2.2	26
9	Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity. <i>Current Drug Targets</i> , 2013, 14, 1322-1328.	2.1	22
10	Yokukansan (TJ-54) for treatment of very-late-onset schizophrenia-like psychosis: An open-label study. <i>Phytomedicine</i> , 2013, 20, 654-658.	5.3	17
11	Analysis of oxidative stress expressed by urinary level of biopyrrins and 8-hydroxydeoxyguanosine in patients with chronic schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , 2015, 69, 693-698.	1.8	17
12	Yi-Gan San for Treatment of Charles Bonnet Syndrome (Visual Hallucination Due to Vision Loss). <i>Clinical Neuropharmacology</i> , 2011, 34, 24-27.	0.7	16
13	Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study. <i>BMC Psychiatry</i> , 2012, 12, 215.	2.6	16
14	Electroconvulsive shock restores the decreased coverage of brain blood vessels by astrocytic endfeet and ameliorates depressive-like behavior. <i>Journal of Affective Disorders</i> , 2019, 257, 331-339.	4.1	15
15	Yokukansan (TJ-54) for Irritability Associated with Pervasive Developmental Disorder in Children and Adolescents: A 12-Week Prospective, Open-Label Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 329-336.	1.3	9
16	Ramelteon as adjunctive therapy for delirium referred to a consultation-liaison psychiatry service: a retrospective analysis. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 994-995.	2.7	9
17	Real-World Preventive Effects of Suvorexant in Intensive Care Delirium. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	8
18	Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 1-11.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Parvalbumin-positive GABAergic interneurons deficit in the hippocampus in Gunn rats: A possible hyperbilirubinemia-induced animal model of schizophrenia. <i>Heliyon</i> , 2019, 5, e02037.	3.2	5
20	The effectiveness of electroconvulsive therapy for psychiatric symptoms and cognitive fluctuations similar to dementia with Lewy bodies: a case report. <i>Psychogeriatrics</i> , 2020, 20, 229-231.	1.2	4
21	Can inhibition of microglial activation cure schizophrenia?. <i>Schizophrenia Research</i> , 2015, 168, 583-584.	2.0	2
22	Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report. <i>Frontiers in Psychiatry</i> , 2018, 9, 260.	2.6	2
23	Normalizing hyperactivity of the Gunn rat with bilirubin-induced neurological disorders via ketanserin. <i>Pediatric Research</i> , 2021, , .	2.3	2
24	Urinary biopyrrins and free immunoglobulin light chains are biomarker candidates for screening atâ€risk mental state in adolescents. <i>Microbial Biotechnology</i> , 2022, 16, 272-280.	1.7	1
25	Low Serum Levels of Fibroblast Growth Factor 2 in Gunn Rats: A Hyperbilirubinemia Animal Model of Schizophrenic Symptoms. <i>CNS and Neurological Disorders - Drug Targets</i> , 2020, 19, 503-508.	1.4	1
26	Studies Support the Use of Suvorexant for the Prevention of Delirium. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	0
27	Efficacy and safety of Ninjinâ€™yoeito (NYT) in treatment-resistant schizophrenia: Open-Label Study. <i>Asian Journal of Psychiatry</i> , 2021, 60, 102662.	2.0	0
28	Contribution of â€œGenuine Microgliaâ€to Alzheimer's Disease Pathology. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 815307.	3.4	0